Aileron Therapeutics, Inc. (ALRN)
NASDAQ: ALRN · Real-Time Price · USD
2.760
-0.060 (-2.13%)
Nov 20, 2024, 4:00 PM EST - Market open
Aileron Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
59.58M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Procaps Group | 414.10M |
Agenus | 160.43M |
Atara Biotherapeutics | 100.44M |
InterCure | 72.42M |
Exagen | 55.75M |
Champions Oncology | 51.66M |
VolitionRx | 1.29M |
Entera Bio | 99.00K |
ALRN News
- 6 days ago - Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 8 days ago - Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - PRNewsWire
- 21 days ago - Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - PRNewsWire
- 5 weeks ago - Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - PRNewsWire
- 2 months ago - Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - PRNewsWire
- 3 months ago - Aileron Therapeutics to Present at the 8th Annual IPF Summit - PRNewsWire
- 3 months ago - Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - PRNewsWire
- 4 months ago - Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - PRNewsWire